FDA Hands Aplicare Warning Letter Over Sterility Controls

Drug Industry Daily
A A
Aplicare landed an FDA warning letter after an inspection uncovered four significant GMP violations involving sterility controls and marketing claims for unapproved uses.

To View This Article:

Login

Subscribe To Drug Industry Daily